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 Satellite cells are dysfunctional in several neuromuscular disorders 
 Some muscles are more susceptible than others to disease and ageing 
 In vitro and in vivo model systems have shed light on many of the processes involved 
in satellite cell function and dysfunction, but the drawbacks of each model system must 
be considered. 
 Skeletal muscle pathology in mouse models of neuromuscular disease are affected by 
genetic background 
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Twenty six participants representing patients, funding agencies and basic and clinical 
scientists involved in research into skeletal muscle stem cells and muscular dystrophies from 
France, Germany, Italy, India, UK, Australia, Spain, USA, The Netherlands and Switzerland 
met in Hoofddorp, The Netherlands on 25 – 27 January 2019. The meeting was held under 
the auspices of the ENMC and ENMC main sponsors, with the additional support of Muscular 
Dystrophy UK. 
 
The central aim of this workshop was to determine whether there could be some intrinsic 
problems with satellite cell function (e.g. activation and myoblast proliferation, differentiation 












major classes of muscular dystrophy and congenital myopathies. This is most likely to 
manifest as impaired muscle formation during development in the congenital myopathies. 
However, some problems in muscle formation may be due to extrinsic factors in the 
microenvironment of the satellite cells/myoblasts, such as altered composition of the 
extracellular matrix. 
 
Although they vary in many features including severity, muscle groups affected, age of onset 
and heart involvement, muscular dystrophies are characterised by progressive skeletal 
muscle weakness and wasting. They are generally caused by mutations in genes that have 
been historically thought to be expressed either only within the muscle fibre to produce 
components of the dystrophin-associated protein complex, or within cells lying outside the 
myofibre (e.g. by fibroblasts (reviewed [1]). Skeletal muscle needs to grow, maintain itself for a 
lifetime and also repair itself in response to injuries or increased load. In muscular 
dystrophies, skeletal muscles undergo chronic intrinsic necrosis that gives rise to myogenesis 
and regeneration, in order to replace the necrotic portion of the myofibres. The satellite cell is 
the stem cell that is involved in regeneration as well as skeletal muscle growth and postnatal 
myogenesis and possibly hypertrophy. It sits in a niche between the myofibre sarcolemma and 
basal lamina both of which regulate satellite cell quiescence, activation and self-renewal. 
 
Expression of several genes responsible for muscular dystrophies but also in congenital 
myopathies were not initially detected in satellite cells. These findings have major implications 
in that they support the idea that muscular dystrophies do not arise from the malfunctioning of 
satellite cells and that correcting other compartments should be sufficient to alleviate the 
disease. However with the advent of powerful detection methods it is becoming clear that this 
conclusion is not generally sustainable. This is best exemplified by discoveries made in the 
field of Duchenne Muscular Dystrophy (DMD).The involvement of the satellite cell in DMD was 
thought to be a secondary response to the lack of dystrophin in the myofibre as well as an 
excessive proliferation of the satellite cells which in human have limted replicative potential 












satellite cells become activated, proliferate and then contribute to muscle regeneration and 
reconstitution of the satellite cell pool. In DMD, it was long held that the satellite cells fail in 
their myogenic capacity and ability to proliferate after repeated episodes of muscle necrosis 
and regeneration. Muscle fibers become progressively replaced by fibrosis an adverse 
environment that also can impair myogenesis. 
 
Recent findings show that dystrophin is expressed transiently in satellite cells and this is 
proposed to control their asymmetric divisions, so that satellite cells from the dystrophin-
deficient mdx mouse model of DMD give rise to a disproportionate number of stem-like 
satellite cells at the expense of differentiation-competent myoblast progenitors [2]. This 
observation raised the possibility of DMD being a muscle stem cell disease. But this may be 
too simplistic, as there appears to be excellent myogenesis and new muscle formation by 
dystrophic satellite cells during growth of mdx mice, and in tissue culture, that is maintained in 
the mdx mouse, even after persistent intrinsic myonecrosis of limb muscles over many months 
and after experimental muscle injury [3], suggesting that dystrophin is not critical for satellite 
cell function under the experimental conditions evaluated. 
 
The satellite cell dysfunction in mouse models of dystroglycanopathy [4] and collagen VI 
deficiency [5] may be due to defects in the environment (niche), rather than intrinsic defects in 
the satellite cells themselves. But the extent to which members of the DAPC are expressed in 
satellite cells and whether their expression within satellite cells is vital for satellite cell function, 
is not clear. 
 
Satellite cells also seem to have some direct effects on their environment and any disturbance 
in this may lead to muscle pathology: it is proposed that satellite cells signal to fibroblasts to 
hold them in quiescence and loss of satellite cells may increase muscle fibrosis. 
 
Mutations in genes that regulate satellite cell/myoblast activity are implicated in some 












fusing to form myotubes let alone myofibres during embrogenesis and early growth results in 
impaired muscle formation evident at birth. 
 
It is essential that we accurately assess the contribution of satellite cells to pathology of 
diverse muscular dystrophies, since current therapies mostly aim at correcting abnormalities 
solely in the myofibre. This, if not addressed, will have major implications on the long term 
efficacy of any treatment; if a defect in satellite cells is either the main, or a contributory, cause 
of a disease, then treating the myofibre will at best be partially successful. 
 
2. Defects in muscle regeneration in different neuromuscular conditions 
 
Duchenne muscular dystrophy: Grounds 
Since skeletal muscle satellite (stem) cell, also called myoblast, transfer therapy has been 
intensively investigated for over 30 years as a possible gene replacement strategy for DMD, 
this talk first summarised the many persisting problems with clinical applications of this muscle 
stem cell therapy approach that need to be overcome. Key issues include the source of 
„normal donor‟ skeletal muscle stem cells, expansion in tissue culture, best route of delivery, 
massivinitial death of injected cultured myogenic cells, and limited proliferation and migration 
in vivo, before fusion with the host dystrophic muscle cells. These major problems need to be 
realistically addressed when proposing stem cell therapies for muscular dystrophies. Another 
therapeutic strategy for delivering myogenic stem cells, is the exciting field of tissue 
engineering that aims to build new muscle constructs to replace muscles that are unable to 
regenerate due to some impaired intrinsic capacity of muscle stem cells; while this holds great 
promise for many creative tissue culture studies of muscle cells, there remain serious 
challenges for clinical applications [8]. 
The critical issue of identifying whether there is any intrinsic problem with satellite cell capacity 
for myogenesis in DMD specifically, and other muscular dystrophies was then addressed. This 
can be identified by some marked problems with muscle formation during development 












Then it is essential to determine histologically the extent of any ongoing intrinsic myofibre 
necrosis (thus the need for regeneration) in growing and adult muscles; however, care is 
needed when assessing biopsies since many morphological changes in muscles that can 
occur over time for other reasons (e.g. split myofibres, central myonuclei) can sometimes be 
misinterpretated as resulting from necrosis/regeneration [9]. If there is extensive intrinsic 
necrosis, as evident in dystrophic rodent and dog models of DMD, then the capacity for 
sustained new muscle formation and regeneration needs to be determined: yet it is widely 
reported that limb muscles of mdx mice have excellent sustained new muscle formation. 
However, one has to be cautious about concluding that the same properties exist in the 
human condition without further evidence. The capacity for myogenesis (proliferation and 
fusion) of the satellite cells can also be examined experimentally; in vitro studies show 
excellent myogenesis (equivalent to normal muscles) even for satellite cells cultured from old 
mdx mice aged 15 months [3], and in vivo studies using experimental muscle injury in mdx 
mice show very similar regenerative capacity for old mdx and normal muscles. 
Thus overall, in animal models and possibly in DMD, these many observations strongly 
indicate no significant intrinsic problem with myogenesis of dystrophic skeletal muscle stem 
cells in vivo. This clearly contrasts with recent claims [2] that need to be carefully re-
considered in the context of this large body of evidence for excellent intrinsic regeneration of 
dystrophic muscles. Instead, the central problem for DMD maybe the repeated necrosis of 
dystrophic muscles over many years, exacerbated by growth for almost 2 decades. While 
necrosis initially results in good regeneration of dystrophic muscles, over time the persistent 
bouts of asynchronous damage and inflammation progressively change the extracellular 
matrix composition with increasing collagen deposition and fibrosis that can impair 
myogenesis and stop regeneration, leading to severe loss of skeletal muscle mass and 
function in DMD boys. 
 
Satellite cell behavior in myotonic dystrophy: Furling 
Myotonic dystrophy type 1 (DM1 or Steinert disease), one of the most common 












the 3‟UTR of the DMPK gene. DM1 is an RNA dominant disorder in which nuclear-retained 
DMPK transcripts containing CUG expansions alter the function of RNA binding proteins. 
Abnormal binding of MBNL proteins to pathologic CUG tract leads to their sequestration within 
nuclear CUGexp-RNA foci and subsequently, to their functional loss that is associated with 
RNA metabolism alterations including alternative splicing misregulations. Interestingly, DM1 
splicing changes in CLCN1, BIN1 and DMD pre-mRNAs are associated with symptoms such 
as myotonia, muscle weakness and dystrophic process, respectively. At the clinal level, five 
forms of the disease (late, adult, juvenile, infantile and congenital) are recognized based on 
the occurrence and onset of symptoms as well as the size of the CTG tract, which correlates 
with severity of symptoms. In addition to myotonia, DM1 skeletal muscles displayed 
progressive weakness and atrophy as well as histological features including increased 
variation of fiber diameter, central nuclei, sarcoplasmic masses, nuclear clumps and ring 
fibers. Although an increased number of satellite cells are found in the more affected muscles, 
several studies support altered behavior of DM1 satellite cells that could impact their 
regenerative capacity and/or muscle mass maintenance. Thus, DM1 muscle precursor cells 
have a reduced proliferative capacity in vitro due to an early activation of the p16-dominant 
pathway leading to premature replicative senescence [10]. Moreover, expression of mutant 
RNAs harboring large CUG expansions alters the myogenic differentiation process of DM1 
myoblasts. Defective differentiation/fusion was observed in myoblasts isolated from muscles 
of severe congenital DM1 patients showing muscle immaturity or delayed muscle maturation. 
Altogether these results suggest that satellite cell functions are progressively impaired by 
unstable CTG expansions, a mechanism that could contribute to the gradual muscle atrophy 
in DM1 pathology. Additional studies are required to determine the role of extrinsic and/or 
intrinsic signals on impaired behavior of satellite cells in DM1. 
 
Satellite cells, DUX4, PAX7 and facioscapulohumeral muscular dystrophy: Zammit 
Facioscapulohumeral muscular dystrophy (FSHD) is characterized by a descending skeletal 
muscle weakness and wasting. This implies that the normal repair functions performed by 












(MIM 158901) are linked to the hypomethylation of D4Z4 repeats on chromosome 4q35. Each 
D4Z4 repeat contains an open reading frame for a retro-transposed transcription factor, 
double homeobox chromosome 4 (DUX4). Such epigenetic de-repression in FSHD leads to 
expression of DUX4 from the most distal D4Z4 unit, with DUX4 message then stabilized by a 
polyA signal located in the flanking pLAM region [11]. DUX4 is a homeodomain-containing 
transcription factor, and its aberrant expression is considered the primary cause of FSHD 
pathology [11, 12]. 
Investigation into how DUX4 drives FSHD pathology has mainly focused on expression of 
DUX4 target genes. However, the homoedomains of DUX4 have high homology to those of 
PAX7 and are interchangeable, suggesting an alternate hypothesis whereby ectopic DUX4 
expression in FSHD interferes with PAX7 function. DUX4 and PAX7 mutually inhibit each 
other in activating their respective transcriptional target genes in human cells [13], while, 
PAX7 can rescue DUX4-mediated apoptosis in murine myoblasts. 
 
Banerji and Zammit have recently found that the repression of PAX7 transcriptional target 
genes is a hallmark of FSHD, proposing a model whereby DUX4 causes pathology not only by 
directly activating its own target genes, but also by interfering with the ability of PAX7 to 
regulate its transcriptional gene target cohort [13]. Indeed, PAX7 target gene repression in 
FSHD correlates with disease severity, independently of DUX4 target gene expression. At the 
single cell level, PAX7 target gene repression can efficiently discriminate FSHD cells, even 
when no DUX4 target genes are detectable [14]. Thus, PAX7 target gene repression is a 
major biomarker for FSHD. Since DUX4 can be expressed in primary FSHD patient-derived 
proliferating myoblasts, such interference of PAX7 function by DUX4 would affect satellite cell 
mediated repair in FSHD. 
Zammit and colleagues also explored FSHD pathomechanisms, particularly the pathways that 
control mitochondria: of interest considering alterations in mitochondrial structure and function 
in FSHD muscle, and the known sensitivity of FSHD cells to oxidative stress. Notably, they 
identified suppression of mitochondrial biogenesis in FSHD, in particular via PGC1alpha, the 












myotubes, with a thin, elongated morphology, or myotubes with an unusual distribution of 
myonuclei and dysregulation of the microtubule network. Known ERRalpha agonists and safe 
food supplements Biochanin A, Genistein or Daidzein can rescue this hypotrophic myogenic 
differentiation in FSHD. Thus suppression of the PGC1alpha-ERRalpha axis leads to 
perturbed myogenic differentiation, which can effectively be rescued by readily-available food 
supplements, which may lead to a regenerative therapy approach for FSHD. 
 
Oculopharyngeal muscular dystrophy: Butler-Browne 
The regenerative capacity of skeletal muscle declines with age – this decline has been partly 
attributed to extrinsic environmental influences and diverse intrinsic potential of the muscle 
stem cells themselves. Age-related muscle decline can be exacerbated in patients with late 
onset degenerative disorders. A progressive loss of function of pharyngeal muscles is 
frequently encountered in ageing subjects (a condition called achalasia) as well as in several 
neurological or neuromuscular disorders. Among them, oculopharyngeal muscular dystrophy 
(OPMD) is a late-onset autosomal dominant degenerative muscle disorder, characterized by 
weakness of eyelids and pharyngeal muscles that typically appear from the fifth decade, 
leading respectively to ptosis and dysphagia. The genetic mutation - a short polyalanine 
expansion in the ubiquitous PABPN1 protein [15] – was found over 20 years ago but the 
pathophysiological mechanisms leading to the specific alterations of the myogenic program in 
these muscles remains to be determined. Butler-Browne reported that, although sharing 
similar functions, all muscles are not equal in terms of structure and presence of satellite cells, 
and among them pharyngeal and eyelid muscles - per se show atypical features, such as 
hypotrophic muscle fibers surrounded by connective tissue that are usually considered to be 
pathological in the other skeletal muscles (limb muscles). Surprisingly, during ageing Butler-
Browne recently demonstrated that pharyngeal muscles have an increased proportion of 
muscle stem cells - 6% compared to the 1% or less classically observed in the limb muscles 
of „old‟ subjects. In addition, they observed the presence of many satellite cells in the 
interstitial space. In the pharyngeal muscles of OPMD patients the number of muscle stem 












signs of ongoing regeneration. Different hypotheses could explain this increased percentage 
of muscle stem cells both inside and outside of their niche, including extrinsic and/or intrinsic 
signals. Butler-Browne presented the different techniques used on human muscle samples: 
gene expression profile studies, co-culture experiments, xenograft models and CyToF to 
decipher the potential mechanisms involved. Preliminary results demonstrate both instrinsic 
and extrinsic signals are involved. The study of the specific signature of pharyngeal muscle 
stem cells which Butler-Browne has observed will further our understanding of what makes 
this muscle more susceptible to diseases and ageing and why the large number of muscle 
stem cell present in these muscles do not help muscle regeneration. Disorders affecting these 
muscles will represent particularly informative models to better understand skeletal muscle 
stem cell homeostasis in adults and in ageing. 
 
POGLUT1 mutation: Paradas 
Padaras discussed recessive mutations in the POGLUT1 gene that have been associated 
with a muscular dystrophy due to decreased Notch signalling and reduced pool of quiescent 
satellite cells, demonstrated in adult skeletal muscle from patients [16]. A direct consequence 
is a slow proliferation and differentiation shown by the mutant human myoblasts, which 
causes an alteration of the muscle repair process. A secondary consequence is a disruption of 
the progressive alpha-dystroglycan glycosylation that physiologically occurs during 
myogenesis [17], potentially participating in the myopathic process. So, the critical role of this 
O-glycosyltransferasa 1 protein, POGLUT1, in the maintenance of a correct pool of satellite 
cells has been uncovered, reinforcing the Notch signalling pathway as a potential therapeutic 
target for this myopathy. Primary myoblast culture and Drosophila have been demonstrated to 
be useful experimental models to study the effects of POGLUT1 mutations on satellite cells. 
Generation of mouse models are in progress, showing promising preliminary results. 
 
Congenital myopathies: Jungbluth 
Jungbluth reviewed the evidence for satellite cell involvement in the congenital myopathies 












by the abundance of certain structural abnormalities – cores, nemaline rods and central nuclei 
– on muscle biopsy. In contrast to the congenital muscular dystrophies (CMDs), the plasma 
membrane integrity is typically preserved, reflected in normal or only mildly elevated CK 
levels. More than 20 genes have been implicated to date, encoding proteins most commonly 
involved in various aspects of excitation-contraction coupling, the process thereby a neuronal 
impulse is translated into intracellular calcium release and muscle contraction. Mutations in 
the skeletal muscle ryanodine receptor (RYR1) gene encoding the principal sarcoplasmic 
reticulum calcium release channel are the most common cause and have been associated 
with a wide phenotypical spectrum, ranging from severe CMs with antenatal onset to induced 
episodic manifestations – malignant hyperthermia and (exertional) rhabdomyolysis – in 
otherwise healthy individuals. 
 
The evidence for satellite cell involvement is strongest in Early-onset Myopathy with Areflexia, 
Respiratory Distress and Dysphagia (EMARDD) due to recessive mutations in MEGF10, 
encoding a protein highly expressed in nerve and skeletal muscle tissues, (in particular in 
activated satellite cells) [7, 18]. The MEGF10 protein plays a role in satellite cell proliferation, 
differentiation and fusion into multinucleated fibres, as supported by the typical muscle biopsy 
appearance of small and poorly fused myofibers in MEGF10-deficient states. MEGF10 is also 
involved in satellite cell self renewal and maintenance of the satellite cell quiescent state. An 
important role in muscle regeneration is evidenced by the dystrophic phenotype in the 
MEGF10 KO mouse, and worsening of dystrophic features in the MEGF10/mdx double KO 
when compared to the respective single mutants. Exaggerated satellite cell loss with aging 
and repeated injury, probably due to a shift to myogenic commitment and a consequently 
inadequately maintained muscle satellite cell pool, has also been observed in recessive 
SEPN1-related myopathies, a group of CMs characterized clinically by predominant axial 
involvement with early scoliosis and respiratory impairment, and increases in connective 
tissue, fibre type disproportion and cores (“Multi-minicore Disease, MmD”) on muscle biopsy. 
SEPN1 encodes Selenoprotein N, a member of a protein group mediating the effects of 












important role in redox regulation. Reflective of the reported satellite cell abnormalities, SelN 
deficiency has been associated with loss of regenerative capacity, muscle mass and strength 
on the organismal level [19]. A reduction of absolute satellite cell numbers has also been 
reported in muscle biopsies from affected humans and animal models of X-linked myotubular 
myopathy (XLMTM), specific qualitative studies have not yet been performed [20]. XLMTM is 
due to X-linked recessive mutations in MTM1, encoding myotubularin with important roles in 
membrane trafficking and other intracellular processes. XLMTM is a severe and often lethal 
early-onset myopathy with clinical features of marked weakness, severe respiratory and 
bulbar involvement, as well as the presence of numerous centralized nuclei and 
predominance of atrophic type 1 fibres on muscle biopsy. 
 
These findings, in conjunction with the recent identification of mutations in PAX7 and MYMK 
(see below), suggest that there is a distinct CM subgroup where satellite cell pathology is 
crucially involved. These CMs are often characterized clinically by marked axial involvement 
and severe respiratory impairment, and predominance of atrophic type 1 fibres and increases 
in connective tissue on muscle biopsy, indicating a consistent phenotype. Level of satellite cell 
assessment (in particular regarding activation states and cell fate commitment) has been 
variable and requires further standardization. The involvement of satellite cells in other CMs, 
and in particular their role in the commonly observed disturbances of muscle growth, remains 
to be elucidated. 
 
Pathological pathways in dystrophic models of DMD and LGMD: van Putten 
van Putten started by pointing out that despite the many similarities in disease pathology 
between muscular dystrophy patients and mouse models (i.e. primary defect, chronic 
cascades of muscle degeneration, regeneration, severe inflammation response and the 
development of fibrosis), there are also many differences. These include amongst others 
differences in growth speed, distribution of bodyweight on limb muscles, a lack of 
development of fat in mice and a general disease stabilization in adulthood. Only in animal 












remains important to keep these differences in mind when conducting basic science 
experiments or pre-clinical studies with animal models; they remain models which each have 
their own limitations. 
 
van Putten then focussed on the muscle pathology in mdx mice, which is characterized by 
cycles of degeneration and regeneration from the age of 3 weeks onwards, after which it 
stabilizes in adulthood due to their relatively good regenerative capacity. Several attempts 
have been undertaken to exacerbate disease pathology by backcrossing mdx mice on another 
genetic background. Based on findings in the gamma-sacroglycan model for LGMD where 
pathology became worse when crossed on a DBA2/J genetic background [21, 22], D2-mdx 
mice were generated. She discussed the „On Mouse And Measures‟ initiative of Charley‟s 
Fund where all available data of this novel DMD model were collected. In short, pathology is 
characterized by early onset of degeneration and regeneration. Overall muscle pathology 
(necrosis, fibrosis, inflammation) is more apparent in the D2-mdx than in the BL10-mdx model 
due to alterations in Ltbp4 (causing fibrosis), Anex6 (impairing regeneration) and genes in the 
dyscalc locus (causing calcification) and potentially other as yet unidentified mutations. In both 
models, severity differs between muscles, with diaphragm being most severely affected and 
tibialis anterior least severely affected. Functional differences (in hanging wire tests) exist 
between genders, with females outperforming males, and BL10-mdx outperforming D2-mdx 
mice. D2-mdx mice have lower counts of centralized nuclei, active regeneration (BrdU and 
eMHC staining). A striking difference between the strains is extensive calcified muscles in D2-
mdx mice [23]. These seem to directly be linked to muscle damage, differ in abundance 
between muscles and these calcifications ameliorate with age (very abundant in 10 week old 
mice, but much reduced numbers at 34 weeks of age). The reason for this is still unknown. 
 
Lastly she discussed muscle pathology in two mouse models for LGMD (sgca-null for 
LGMD2D and sgcd-null for LGMD2F). A striking difference between the strains is that muscle 
function in sgca-null males and females is affected to the same extent, while in sgcd-null mice, 












ages, although again diaphragm is most severely affected in these strains. In these models, 
muscle regeneration is active in the young age (8 weeks), but decreases in adult mice (24 
weeks). 
 
3. Models of satellite cell in involvement in muscle regeneration 
 
The workshop dedicated one session to discuss models to study satellite cell function in a 
spectrum of models. In the mdx mouse, Partridge presented alternative approaches to 
investigate growth and repair of skeletal muscle in animal models. This consisted of 
monitoring the rates of increase in number of myonuclei in fibres extracted from the extensor 
digitorum longus (EDL) muscle and of measuring the amounts of muscle generated by 
satellite cells labelled with BrdU over known time periods. 
 
The former protocol was used to establish the rates of input from myogenic cells over the 
periods of growth in the immediate postnatal period, in the juvenile growth period in normal 
wild-type mice and the initial period of muscle repair and regeneration in different strains of 
dystrophic mouse. It showed that the contribution of satellite cells to muscle growth during the 
3-4 week postnatal period was closely comparable in dystrophic mdx and in non-dystrophic 
wild-type mice. It also showed, unexpectedly, that the addition of new myonuclei to normal 
muscle continued at a slow rate, during growth up to 14 weeks of age and that in the mdx 
mice, myonuclei were added to each fibre at twice this rate to achieve a doubling of myonuclei 
per unit volume. 
The BrdU labelling investigations showed that, during the early phase of the disease, mdx 
mouse muscle undergoes a progressive replacement of some 5-10% of its muscle fibres 
every 3 days, and fully regenerates each necrotic lesion on the basis of 3 days of myogenic 
cell proliferation. This measure of myogenesis demonstrates a clear distinction between the 
very rapid and complete repair of muscle lesions in the C57Bl-mdx mouse from a barely 
detectable repair process in the DBA/2J-mdx mouse. The latter dystrophic mouse model also 












resolved, accompanied by an early onset of endomysial fibrosis. These features make the 
DBA-mdx mouse an interesting new animal model in which to analyze inhibition of myogenic 
repair and accompanied by calcification and fibrosis. 
 
Cell transplant models: Morgan 
Morgan reviewed pre-clinical work on freshly-isolated satellite cells derived from either normal, 
mdx or Largemyd mice (models of DMD and dystroglycanopathy respectively). When 
transplanted into pre-irradiated muscles of immunodeficient mdx mice, freshly isolated donor 
satellite cells behave as stem cells, contributing to muscle regeneration and functionally 
reconstiting the satellite cell pool. Although satellite cell numbers decline over the lifespan and 
the vast majority are activated in growing, 2-week old muscles [25], donor satellite cells 
derived from mice from 2 weeks to 2 years of age engraft equally well when transplanted into 
young immunodeficient mdx irradiated muscles. The host muscle environment has a profound 
effect on donor satellite cell-mediated muscle regeneration, with irradiation being the only host 
muscle pre-treatment that mediated significant engraftment [25]. The environment in which 
satellite cells reside has a profound effect on their performance, but when removed from the 
pathological environment, satellite cells from Largemyd mice function well in vitro [4] and 
satellite cells derived from aged mdx mice contribute as well to functional satellite cells as do 




Dropophila models: Chaturvedi. 
Drosophila have recently become a viable model for studying muscle repair with the 
demonstration of satellite cells in adult muscles. Their mononucleate morphology, adjacency 
to muscle fibers, proliferation upon physical trauma, fusion of their progeny with damaged 
muscles, and lineage shared with adult mature muscle, motivate further inquiry into their 
function. Specifically, their role in muscle repair remains to be assessed through i) satellite cell 












factor Zfh1 is the only identified marker of satellite cells in Drosophila. Interestingly, recent 
work has documented the expression of Zfh1 in mouse satellite cells and evidenced that this 
gene is required for muscle regeneration [26]. Expression of the fly homolog of the 
mammalian satellite cell marker Pax7, has not been reported in Drosophila. A rigorous 
molecular comparison and contrast with mammalian satellite cells will become possible 
through transcriptomic analyses. 
To examine changes in morphology that may result from physical damage or dystrophy, 
Chaturvedi has standardised a protocol to visualise adult Drosophila muscles in situ in 3-
dimension, through MicroCT scanning. Quantitation of these images have revealed definite 
and consistent differences in muscle morphology within, and between, male and female 
Drosophila with age. 
 
At this workshop, many aspects human myopathies, specifically mutations in dystrophy 
patients were highlighted. Further, aspects of Drosophila muscle anatomy that need further 
exploration for an accurate comparison with human muscular dystrophies became clear. 
Taken together, the identification of adult satellite cells in Drosophila, the new technical ability 
to accurately measure morphology with the plethora with in vivo genetic perturbation 
techniques, have all positioned Drosophila as a good in vivo model system for human 
myopathy and muscle repair. 
 
Zebrafish models: Wood 
Wood presented work on three aspects of neuromuscular disease reseach using zebrafish as 
an animal model. Firstly he discussed that the dystrophin-associated glycoprotein complex 
(DGC) is highly conserved in zebrafish. The small tropical fresh water zebrafish has been 
used in muscular dystrophy research since 2003 when the DMD fish sapje was first 
characterised. Since this time, the most common forms of muscular dystrophy have been 
identified from ENU mutagenic screens or modelled with CRISPRs, TALENs and ZFNs, the 
field has moved away from antisense morpholino technology despite several well controlled 












the exception of fish models of laminopathies. Briefly discussed was the fact that FSHD is a 
particularly problematic muscular dystrophy to model in fish. 
Secondly he highlighted that transgenic muscle stem cell and progenitor lines exist. The Tol2 
system has been used to create Tg(pax3a:EGFP), TgBAC(pax7a:EGFP), Tg(met:mCherry-
2A-KALTA4), and Tg(myf5:EGFP) myf5 lines. Zebrabow line Tg(ubb:LOX2272-LOXP-RFP-
LOX2272-CFP-LOXP-YFP) crossed onto a tamoxifen inducible mesogenin cre Tg(mgsn1: 
CreERT2) line can be used to show in the fish model normal cell division in muscle is 
asymmetric but in regenerating fiber there is symmetric division at the injury site [28], in 
confirmation of the work on Prof. Terry Partridge‟s mouse model presented earlier in the 
session. Currently not many DGC lines have been crossed onto these transgenic lines, 
despite general enthusiasm, due to the time consuming nature of these experiments, that 
would require additional grant funding. This study would establish overall stem cell 
contribution to muscular dystrophy pathology and highlight novelties between muscular 
dystrophy models. 
Lastly he had a case for fish being a good model to study fiber detachment in muscular 
dystrophies. Due to optical transparency and ex-utero development it is possible to study 
basement development in various muscular dystrophy fish models, CMD models are 
particularly well suited to the zebrafish system. This may be critical in understanding 
basement membrane failure in fiber detachment and fibrosis. It was noted that Evans blue dye 
is particularly effective to investigate sarcolemma integrity. Physiology measurements such as 
passive and active force are achievable in fish models [29]. A question arose around whether 
it is possible to exacerbate the phenotype. Four options were identified: cellulose, 
electroshock and caffeine in larvae, in adult a swim tunnel can be employed. Zebrabox can 
measure key functional swimming parameters. A final point was made around understanding 
the role tenocytes play in fiber stability and cross talk with muscle progenitor cells and how 
little we know about this cell types contribution to muscular dystrophy. 
 
4. Extracellular Matrix and Fibroblast influence on Satellite cell activity 












Collagen VI (COL6) is an extracellular matrix protein with a unique structural organization and 
playing a remarkably broad range of functions in several tissues, including skeletal muscle. 
Although COL6 expression in muscles is mainly provided by interstitial fibroblasts, its proper 
deposition is critical for myofiber homeostasis, and mutations of COL6 genes are causative for 
human congenital myopathies such as Bethlem myopathy and Ullrich congenital muscular 
dystrophy. In the last two decades, a number of studies in COL6 null (Col6a1–/–) mice have 
shed light into the pathophysiological mechanisms of COL6-related disorders. COL6 
deficiency affects key intracellular pathways, leading to defective regulation of autophagy, 
accumulation of dysfunctional organelles and spontaneous apoptosis [30, 31]. 
Based on the close contact of COL6 microfibrillar network with myofiber sarcolemma and its 
distinctive deposition in muscle endomysium, further studies revealed that this matrix 
molecule plays a pivotal role for satellite cells. Indeed, COL6 is a component of the satellite 
cell niche, which is expressed by quiescent satellite cells in a regulated manner and is 
required for the proper self-renewal of satellite cells both in physiological conditions and 
during muscle regeneration. In vivo and in vitro studies in Col6a1–/– mice demonstrated that 
COL6 is involved in the fine regulation of the biomechanical properties of skeletal muscle, and 
this is one mechanism through which COL6 influences the maintenance of satellite cell 
stemness [5]. In unpublished work with myoblast and satellite cell cultures, Bonaldo‟s team 
found that treatment with soluble COL6 is able to counteract myogenic differentiation and 
increase the incidence of Pax7-positive cells differentiation, pointing at a biochemical effect on 
signaling pathways. Altogether, these data indicate that COL6 has a dual function for skeletal 
muscle on one hand it is critical for the regulation of the mechanical properties of muscle, and 
on the other hand it transduces specific signals with satellite cells.  
Separate work revealed that COL6 regulates macrophage recruitment and polarization. In 
unpublished studies, Bonaldo reported that COL6 ablation impairs macrophage recruitment 
and M2 polarization after muscle injury, pointing at a further independent role of this matrix 












These findings strengthen the concept that COL6 plays multiple functions for skeletal 
muscles, and besides influencing myofiber homeostasis and regulating satellite cell activities it 
also plays a critical role in the inflammatory process and tissue repair during muscle 
regeneration. A major point arising during the discussion of this presentation was indeed 
related to the scarce consideration thus far given to macrophages in muscle regenerative 
processes both in physiological and pathological conditions, and the need to increase our 




LAMA2-related Muscular Dystrophy (LAMA2 muscular dystrophy) or merosin-deficient 
Congenital Muscular Dystrophy 1A (MDC1A) is a severe, early onset and fatal muscular 
dystrophy that is caused by mutations in the gene coding for laminin-α2. Muscles of LAMA2 
muscular dystrophy patients undergo severe muscle degeneration and show a high degree of 
fibrosis. Laminins are a family of heterotrimeric molecules that are major components of the 
extracellular matrix. Laminin-α2 is mainly found in the basement membrane of the skeletal 
muscle and in the endoneurium of the peripheral nerve. The lack of laminin-α2 results in the 
compensatory expression of the developmental laminin-α4. Biochemical studies have shown 
that laminin-α4 lacks the binding to the laminin-α2 receptors, such as α-dystroglycan and α7 
integrin. In addition, laminin-α4, in contrast to laminin-α2, does not self-polymerize. Two 
specifically designed linker proteins can alleviate both of these shortcomings of laminin-α4. 
One linker, termed mini-agrin, binds to the coiled-coil region of laminin and to α-dystroglycan. 
The second linker, a chimera between the LN domain of laminin-α1 and the laminin-binding 
domain of nidogen, allows self-polymerization. When expressed in skeletal muscle fibers, both 
linkers are incorporated into the muscle basement membrane and confer stable association of 
laminin-α4 with the basement membrane and the binding to the plasma membrane of the 
muscle fibers. As a consequence, the two linkers improve the health of LAMA2 mice to a large 
degree as shown in recent proof-of-principle studies in mice [32, 33]. Another feature of the 












despite the high extent of muscle degeneration. This raises the question whether this 
regeneration deficit is based on cell-intrinsic alterations of muscle satellite cells to regenerate 
or on changes in the environment. Interestingly, the two linkers although not expressed in 
muscle satellite cells, greatly improve cardiotoxin-induced muscle regeneration in LAMA2 
muscular dystrophy, suggesting rather extracellular cues being important to improve 
regeneration. In summary, the presented experiments are strong evidence that LAMA2 
muscular dystropy is based on the failure to properly assemble muscle basement membrane 
and to connect it to the muscle fiber membrane. The fact that the cDNAs encoding the two 
linkers are small enough to be incorporated into AAV vectors, make it possible to translate this 
strategy into the clinic. 
 
5. Regulation of satellite cells in development, postnatally and in neuromuscular 
diseases 
Oscillations of MyoD and Hes1 proteins regulate the maintenance of activated muscle stem 
cells: Birchmeier 
The balance between proliferation and differentiation of muscle stem cells is tightly controlled, 
ensuring the maintenance of a cellular pool needed for muscle growth and repair. Notch 
signaling provide important cues that regulate this balance. In mice, mutation of components 
of the Notch signaling pathway result in deficits in muscle growth, a loss of the muscle stem 
cell pool and severe regeneration deficits [34] [35, 36]. In humans, mutation of the POGLUT1 
(protein O-glucosyltransferase 1) gene which encodes an enzyme involved in posttranslational 
Notch modification, causes an autosomal recessive limb-girdle muscular dystrophy. 
Birchmeier showed during her presentation that the direct Notch target gene Hes1 controls the 
balance between proliferation and differentiation of activated muscle stem cells in both, 
developing and regenerating muscle of mice. She showed that Hes1 is expressed in an 
oscillatory manner in activated stem cells where it drives the oscillatory expression of MyoD. 
MyoD expression oscillates in activated muscle stem cells from postnatal and adult muscle 
under various conditions: when the stem cells are dispersed in culture, when they remain 












cells differentiate, MyoD oscillations become unstable and instead long periods of sustained 
MyoD expression are observed. Similarly, when stable MyoD oscillations are experimentally 
disturbed, for instance by ablation of the Hes1 oscillator, activated muscle stem cells 
differentiated with higher probability. This precocious differentiation interfered with the 
maintenance of the muscle stem cell pool, and impaired muscle growth and repair. Analysis 
indicates that the oscillatory expression of MyoD allows activated myogenic stem cells to 
remain in a proliferative state. However, when MyoD oscillations become unstable and are 
replaced by sustained MyoD expression, cells are driven out of the proliferating state and 
differentiate [37]. Thus, oscillatory MyoD expression allows for the amplification of the 
activated stem cell pool to ensure correct muscle growth and regeneration. Birchmeier 
investigated a mechanism that causes muscular dystrophy when disturbed in humans (i.e. 
aberrant Notch signaling), and demonstrates the importance of the balanced 
proliferation/differentiation of muscle stem cells in muscle growth and repair. 
 
Postnatal regulation of satellite cells: Relaix 
In recent years, it has been established that quiescence is not a dormant state - as previously 
thought - but rather a dynamic one, that is maintained by the activity of several different 
pathways. Stem cells in most adult tissues are sustained quiescent under homeostatic 
conditions by the combination of factors that are provided by the specialised 
microenvironment, also known as niche. Identifying the diverse factors of the niche and their 
modes of interaction is a major challenge and a prerequisite for the use of muscle stem cells 
in regenerative medicine. One major obstacle for the study of quiescent cells is that any 
perturbation of the niche triggers a fast activation, which is manifested by swift transcriptional 
and epigenetic changes. To overcome this, Relaix has developed a novel protocol that 
permits the isolation of quiescent satellite cells in their in vivo state. Based on this new 
approach, we have performed a series of high throughput and single cells experiments that 
identify the major players of the quiescence and activation networks, including in preclinical 












Several new approaches to the treatment of DMD are on the pathway to approval and 
development. A critical step is first determining efficacy or safety by using an animal model of 
the disease. These are most useful in preclinical study when they recapitulate the clinical 
condition as observed in human patients. Indeed, dissimilarities between the disease in 
humans and animals may be one cause of the high failure rate, where therapies appear to 
improve a condition in the model, but show poor clinical efficacy. Relaix therefore generated a 
rat model (R-DMDdel52) where the deletion mimics those found in a significant portion of 
patients, followed by a rigorous characterisation of the phenotype. Overall, Relaix observed a 
severe and progressive disease, in keeping with what is seen in patients affected by DMD, 
and death around one year of age associated with loss of muscle mass. R-DMDdel52 rats 
display dystrophin-deficiency, associated with histopathological changes seen in severely 
affected DMD muscle, including increased fibre size variability with the presence of many very 
small and hypertrophic fibres, increased centronucleation, increased fibrosis and necrosis. 
Altogether, these results suggest that R-DMDdel52 is a an interesting preclinical model for 
DMD. 
 
Carey-Fineman-Ziter Syndrome: Bonneman 
This syndrome was originally described in two siblings with bilateral facial weakness and 
Robin sequence (mandibular hypoplasia, hypoglossia, cleft palate), as well as mild proximal 
weakness with small muscles, delayed motor milestones, scoliosis, and normal intelligence. 
As part of an investigation into genetic causes for Moebius syndrome biallelic mutations in the 
gene myomaker/TMEM8C were identified in the original family as well as in four additional 
families with a total of 8 patients [6]. The clinical phenotype was fairly consistent with 
prominent congenital bifacial weakness but without prominent ophthalmoplegia, prominent 
axial weakness and milder involvement of extremity muscles. Muscle biopsy analysis was 
consistent with fiber type disproportion with smal type I fibers and unusually large type II 
fibers. Myomaker has been shown to be critical for myoblast fusion, while germline 
inactivation in the mouse causes prenatal lethality with muscles consisting of unfused single 












complete loss of myomaker, consistent with the notion that a complete loss of myomaker 
function would also not be compatible with postnatal human life. Myomaker is required on 
both cells involved in the fusion process, while the more recently discovered pore forming 
peptide myomixer/myomerger/minion is only required on one of the two fusing cells. While the 
knock out mouse model is histologically very similar to the myomaker knock out situation, no 
human equivalent condition has yet been described. Given that myomaker would also be 
predicted to be required for satellite cell fusion into the myofiber, Carey-Fineman-Ziter 
Syndrome can be conceptualized as a disorder of muscle satellite cells, with presumed 
pathogenic mechanisms in both development as well as in later skeletal musclemaintenance. 
Hypomorphic mouse models will be needed to investigate these important questions in detail. 
The selective involvement early on of facial and axial muscles is striking and raises additional 
interesting developmental questions. 
 
Understanding satellite cell regenerative decline with aging: Muñoz-Cánoves 
The regenerative function of satellite cells declines with aging. Results from Muñoz-Cánoves‟s 
group have shown that quiescent satellite cells have a constitutive autophagic activity that allows 
them to maintain the correct intracellular balance between synthesis and degradation of proteins 
and organelles [38]. This basal autophagy is essential to preserve satellite cell homeostasis and 
proliferative capacity to generate new muscle fibers upon tissue injury. Muñoz-Cánoves observed 
that autophagy is decreased in satellite cells of aged mice, affecting their internal cleansing 
process. As a result, they observed that the intracellular accumulation of damaged proteins and 
organelles such as mitochondria could not be eliminated correctly, triggering a switch from 
quiescence to a senescence-like state. Muñoz-Cánoves found that pharmacological or genetic 
restoration of autophagy in aged satellite cells allowed them to recover their regenerative 
capacity and escape senescence. Conversely, genetic inhibition of autophagy in quiescent young 
satellite cells caused senescence entry [39]. Since damaged mitochondria are one of the main 
sources of reactive oxygen species (ROS), the decrease in mitophagy activity associated with 
age led to an increase in oxidative stress. Treatment with antioxidants led to 












damaged components and entry into senescence, ultimately restoring the regenerative capacity 
of aged satellite cells. Of note, Muñoz-Cánoves found that a caloric restriction regime in old mice 
increased satellite cell regenerative functions, at least in part by promoting autophagy 
(unpublished results). In conclusion, they have shown that autophagy is essential to maintain 
"stemness". Their more recent results indicate that autophagic activity is also impeded in satellite 
cells of mdx dystrophic mice, correlating with increased cellular senescence (unpublished 
results). Therefore, enhancing the regenerative capacity of satellite cells through the 
pharmacological or dietary activation of autophagy, or reduction of senescence, opens the 
possibility to future regenerative therapies in the context of muscle regeneration problems 
associated with aging or muscular dystrophies. 
 
Novel mouse models to study dystrophin in control and disease context: Helge Amthor 
Dmdmdx is a frequently used mouse model for DMD and dystrophin-restoring therapies. 
Amthor made a strong case that current translational research is methologically limited by 
antibody-mediated signal amplification to visualize dystrophin. Amthor shared unpublished 
data on DmdEGFP carrying a C-terminal EGFP-tag and a DmdEGFP-mdx reporter mouse line 
carrying additionally in cis the mdx-23 mutation, which were generated in collaboration with 
the laboratory of Markus Schuelke in Berlin. These novel models facilitate the study of 
dystrophin expression/restoration not only at sarcolemmal level, but also in neuromuscular 
junction, myotendinous junction and muscle stem cells, which are central components of 
skeletal muscle and required for its excitation, force transmission and regeneration. Helge 
Amthor argued that dystrophin restoration at critical sites of expression is required for 
therapies to be effective. However, current standards of dystrophin quantification in preclinical 
models and those from clinical research studies may only be partially addressing this issue. 
Novel methods are required to improve imaging of dystrophin restoration not only at the 
sarcolemma but also other key sites listed to better predict benefites of a therapy. 
 












Lorenzo Giordani attended the workshop as a special young scientist delegate. He highlighted 
that skeletal muscle repair requires the activation of resident stem/progenitor cells (satellite 
cells) that can both self-renew and generate differentiated progeny. To correctly execute the 
regenerative program, satellite cells interact with their microenvironment and require signals 
from neighboring cells. However, in pathologic contexts such as degenerative myopathies 
(e.g. DMD) the efficiency of this process progressively declines leading ultimately to 
incomplete repair, fat infiltration and fibrotic scarring. Understanding the cellular mechanisms 
behind regeneration impairment is pivotal to the development of novel strategies aimed at 
slowing down and counteract disease progression. Standard bulk-scale methods had been 
proven unfit to address these questions since are unable to correctly render the heterogeneity 
within the populations involved in tissue repair. As a result, defective disease-specific 
subpopulations remain most of the time undetected. Hence the need to apply a single-cell 
approach to identify those dysfunctional subsets. 
 
Giordani presented a two-step strategy to study the different resident populations in skeletal 
muscles and identify those potentially involved in the regeneration impairment. First single-cell 
transcriptomics and mass cytometry (CyTOF) analyses have been used to attain a clearer 
understanding of the cellular composition of adult skeletal muscle, leading to the identification 
of muscle resident tenocyte-like cells (SCX+) as well as a non-multipotent myogenic subset of 
mesenchymal helper cells. Then, using different algorithms (SPADE, Statistical Scaffold) 
Giordani overlaid the initial single cell blueprint on both the dystrophic (MDX4cv) and the aged 
condition. This revealed functional similarities and highlight recurring patterns. Lastly, as proof 
of concept he showed some preliminary data on CyTOF on human biopsies. The data 
presented demonstrate that this approach could be successfully applied to any tissue. In 
particular, in pathologic conditions, it could serve to precisely identify dysfunctional 
subfractions [40]. 
 
This two-step approach could be used to study the specific role of satellite cells and other 












technologies (such as mass cytometry) to clinicians could be instrumental to build a 
collaborative network to successfully apply this approach to different specific muscular 
dystrophies. 
 
6. Funder’s and Patient perspective 
 
Funder’s perspective: Stevenson 
Alison Stevenson, Senior Grants Manager at Muscular Dystrophy UK, spoke about the 
charity‟s work for people with neuromuscular conditions, its research strategy and funding 
opportunities. 
Muscular Dystrophy UK is the UK‟s largest charity for people with muscular dystrophy and 
related neuromuscular conditions, and has an annual income of over £7million. Approximately 
70,000 people in the UK are affected by muscular dystrophy or a related neuromuscular 
condition. 
 
The charity provides information, advocacy and other support to enable individuals affected by 
these conditions to live as independently as possible, because for people living with a muscle-
wasting condition every day counts. Muscular Dystrophy UK‟s recent strategy outlines four 
priority areas of working for the coming three years: Fast Track to treatments, mental health 
matters, advances in technology, sport, leisure and exercise. 
 
The charity also funds research into the causes and potential treatments for these conditions, 
from basic to preclinical to clinical studies. Funding for research projects is primarily for UK 
researchers and is awarded through a rigorous, competitive process involving peer review and 
assessment by the charity‟s Medical Research Committee and Lay Research Panel. Lay 
summaries must be provided by applicants and are scored by the Lay Research Panel 













Alison finished by reflecting on the questions raised by members of the Lay Research Panel 
around stem cells in muscular dystrophy. Their comments focussed on the need and desire 
for a potential treatment, and questions were raised about how this would work. For example, 
what would a stem cell treatment look like, what would the source of stem cells be, how often 
would a treatment be administered and how would a balance be reached between the need 
for immune suppression and the risk of infection? Other considerations were: who would be 
eligible (treatments should be inclusive of children) and how to ensure a quick route to market. 
Alison acknowledged that much research is currently at a basic level, rather than developing 
stem cells as potential treatments, but noted it would be important to bear these comments 
and questions in mind for the workshop discussions and for future research. 
 
Patient’s perspective: Davenport 
Richard Davenport explored some personal reflections on the effects of muscular dystrophy 
on his life, pain, rehab and the many changes it brings. He suggested that self-image, our 
perceptions of ourselves and how we fit into the world, can be really influential in managing 
the condition but also challenged by those changes. So much so, that bigger physical 
changes leave our self-image with a gap in meaning and a certain amount of reinvention and 
resocialisation takes place to fill it. Because life with muscular dystrophy is relentless change 
and adaption, regular focused counselling, from diagnosis, could greatly assist patients in 
proactively managing these sometimes existential challenges. 
Aside from the individual-focused changes and challenges, Richard also talked about how 
access becomes critical but the prevalent attitude to access is one of ineffective apology or 
flat nonchalance. These sorts of "social model" issues become a daily grind as much as the 
physical struggles. 
 
7. Final remarks 
 
This workshop has shed light on stem cell involvement in the pathogenesis of muscular 












 The involvement of satellite cells in experimental models and humans, particularly the 
importance of rigorously evaluating all in vitro data in the context of what actually 
occurs in vivo. 
 The fate and biology of satellite cells during ageing and in disease. For old muscles, a 
large body of data indicate no major intrinsic problem in myogenic capacity of satellite 
cells, especially in vivo: this is controversial. However, major age-related alterations to 
the inflammatory cell response are well documented, with adverse effects on the 
kinetics of regeneration after experimental injury of old muscles. Furthermore, there 
appears to be minimal incidence of necrosis/ regeneration in healthy old human and 
mouse muscles (and thus no ongoing myogenesis and regenerating host myofibres to 
fuse with donor myoblasts in any proposed stem cell therapy). 
 The role of satellite cells in development of muscle pathology in DMD, Limb Girdle 
Muscular Dystrophy and other muscular dystrophies. Much data indicate no major 
intrinsic myogenic stem (satellite) cell problem in vivo for DMD and LGMD2B. The 
controversy over stem cell deficits in DMD may be due to differences in in vivo and in 
vitro environments. 
 The impact of metabolism on the muscle repair programme. The work presented here 
showed that reducing organismal energy levels promotes satellite cell function in 
mouse models of DMD, whereas other previous work has documented the benefits of 
high fat diets in supporting muscle fibre repair. 
 The evidence of defective satellite cells as primary cause of EMARDD and CFZ 
Syndrome. 
 The efficacy of therapeutic strategies to correct satellite cell dysfunction in muscular 
dystrophies. For this to be effective, any intrinsic problem with satellite cells in 
dystrophic muscles in vivo must be fully understood. Major problems are well-
documented for stem cell transplantation therapy for DMD. For DMD, we may need to 
target the extracellular matrix (fibrosis) to improve regeneration. Preventing necrosis in 












defects in satellite cells in either DMD or some of the congenital muscular dystrophies 
are future possibilities. 
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